

JosÃ© Alberto Navarro-GarcÃ­a

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2546557/publications.pdf>

Version: 2024-02-01

19
papers

222
citations

1163117

8
h-index

1058476

14
g-index

19
all docs

19
docs citations

19
times ranked

235
citing authors

#	ARTICLE	IF	CITATIONS
1	The anti-aging factor Klotho protects against acquired long QT syndrome induced by uremia and promoted by fibroblast growth factor 23. <i>BMC Medicine</i> , 2022, 20, 14.	5.5	7
2	Interplay between mineral bone disorder and cardiac damage in acute kidney injury: from Ca ²⁺ mishandling and preventive role of Klotho in mice to its potential mortality prediction in human. <i>Translational Research</i> , 2022, 243, 60-77.	5.0	5
3	Murine models of uremic cardiomyopathy as a necessary tool to unravel mechanisms involved in cardiorenal syndrome. <i>Kidney International</i> , 2022, 101, 214-216.	5.2	1
4	Unilateral Acute Renal Ischemia-Reperfusion Injury Induces Cardiac Dysfunction through Intracellular Calcium Mishandling. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2266.	4.1	7
5	Soluble Klotho and heparin modulate the pathologic cardiac actions of fibroblast growth factor 23 in chronic kidney disease. <i>Kidney International</i> , 2022, 102, 261-279.	5.2	16
6	An Overview of FGF-23 as a Novel Candidate Biomarker of Cardiovascular Risk. <i>Frontiers in Physiology</i> , 2021, 12, 632260.	2.8	39
7	Analysis of Global Oxidative Status Using Multimarker Scores Reveals a Specific Association Between Renal Dysfunction and Diuretic Therapy in Older Adults. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 1198-1205.	3.6	4
8	Fibroblast Growth Factor-23-Klotho Axis in Cardiorenal Syndrome: Mediators and Potential Therapeutic Targets. <i>Frontiers in Physiology</i> , 2021, 12, 775029.	2.8	5
9	Genetic Deletion of NOD1 Prevents Cardiac Ca ²⁺ Mishandling Induced by Experimental Chronic Kidney Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8868.	4.1	5
10	Oxidized Low-Density Lipoprotein Associates with Ventricular Stress in Young Adults and Triggers Intracellular Ca ²⁺ Alterations in Adult Ventricular Cardiomyocytes. <i>Antioxidants</i> , 2020, 9, 1213.	5.1	7
11	Enhanced Klotho availability protects against cardiac dysfunction induced by uraemic cardiomyopathy by regulating Ca ²⁺ handling. <i>British Journal of Pharmacology</i> , 2020, 177, 4701-4719.	5.4	24
12	Beneficial effects of paricalcitol on cardiac dysfunction and remodelling in a model of established heart failure. <i>British Journal of Pharmacology</i> , 2020, 177, 3273-3290.	5.4	10
13	Variations in Circulating Active MMP-9 Levels during Renal Replacement Therapy. <i>Biomolecules</i> , 2020, 10, 505.	4.0	3
14	Lifetime cardiovascular risk is associated with a multimarker score of systemic oxidative status in young adults independently of traditional risk factors. <i>Translational Research</i> , 2019, 212, 54-66.	5.0	8
15	Association between renal dysfunction and metalloproteinase (MMP)-9 activity in hypertensive patients. <i>Nefrologia</i> , 2019, 39, 184-191.	0.4	6
16	Oxidative Status before and after Renal Replacement Therapy: Differences between Conventional High Flux Hemodialysis and on-Line Hemodiafiltration. <i>Nutrients</i> , 2019, 11, 2809.	4.1	13
17	Fibroblast growth factor-23 promotes rhythm alterations and contractile dysfunction in adult ventricular cardiomyocytes. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1864-1875.	0.7	40
18	Asociación entre disminución de la función renal y actividad metaloproteínasa-9 en el paciente hipertenso. <i>Nefrologia</i> , 2019, 39, 184-191.	0.4	8

#	ARTICLE	IF	CITATIONS
19	Rapid, Automated, and Specific Immunoassay to Directly Measure Matrix Metalloproteinase-9's Tissue Inhibitor of Metalloproteinase-1 Interactions in Human Plasma Using AlphaLISA Technology: A New Alternative to Classical ELISA. <i>Frontiers in Immunology</i> , 2017, 8, 853.	4.8	14